Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Grunenthal Acquires Rights to Zomic from AstraZeneca 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 16
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 17
Venture Financing 18
Thar Pharma Raises USD0.12 Million in Venture Financing 18
Thar Pharma Raises Additional USD2 Million in Venture Financing 19
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 20
Thar Pharma Raises Additional US$0.08 Million In Venture Financing 21
Partnerships 22
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 22
Grunenthal and KU Leuven Enter into Research Agreement 24
Grunenthal Enters into Distribution Agreement with Merck 25
Helsinn and Grunenthal Enter into Agreement for Akynzeo 26
Grunenthal Enters into Agreement with Axxam 27
Patheon Enters into Co-Development Agreement with Grunenthal 28
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 29
Thar Pharma Enters into Co-Development Agreement 30
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 31
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 32
Grunenthal Enters into Agreement with Proteus and Boston Children’s Hospital 33
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 34
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 35
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 37
Licensing Agreements 38
Mundipharma Enters into Licensing Agreement with Grunenthal 38
Grunenthal Enters into Licensing Agreement with AstraZeneca 39
Mundipharma Enters Into Licensing Agreement With Grunenthal 40
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 42
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 43
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 44
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 45
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 46
Equity Offering 47
Thar Pharma Postpones IPO for USD50 Million 47
Asset Transactions 49
Depomed Acquires Rights of Cebranopadol from Grunenthal 49
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 51
Acquisition 53
Grunenthal Acquires Thar Pharma 53
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 54
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 55
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 56
Grunenthal GmbH – Key Competitors 57
Grunenthal GmbH – Key Employees 58
Grunenthal GmbH – Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Recent Developments 62
Strategy And Business Planning 62
May 10, 2017: Grünenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 62
Corporate Communications 63
Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group 63
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 64
Government and Public Interest 65
Nov 16, 2017: Research Consortium led by Grünenthal receives € 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia 65
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients’ Lives – EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 66
Product News 67
Jul 07, 2017: Grünenthal Group: Launch of the Project – Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal Acquires Rights to Zomic from AstraZeneca 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 16
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 17
Thar Pharma Raises USD0.12 Million in Venture Financing 18
Thar Pharma Raises Additional USD2 Million in Venture Financing 19
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 20
Thar Pharma Raises Additional US$0.08 Million In Venture Financing 21
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 22
Grunenthal and KU Leuven Enter into Research Agreement 24
Grunenthal Enters into Distribution Agreement with Merck 25
Helsinn and Grunenthal Enter into Agreement for Akynzeo 26
Grunenthal Enters into Agreement with Axxam 27
Patheon Enters into Co-Development Agreement with Grunenthal 28
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 29
Thar Pharma Enters into Co-Development Agreement 30
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 31
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 32
Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 33
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 34
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 35
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 37
Mundipharma Enters into Licensing Agreement with Grunenthal 38
Grunenthal Enters into Licensing Agreement with AstraZeneca 39
Mundipharma Enters Into Licensing Agreement With Grunenthal 40
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 42
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 43
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 44
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 45
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 46
Thar Pharma Postpones IPO for USD50 Million 47
Depomed Acquires Rights of Cebranopadol from Grunenthal 49
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 51
Grunenthal Acquires Thar Pharma 53
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 54
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 55
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 56
Grunenthal GmbH, Key Competitors 57
Grunenthal GmbH, Key Employees 58
Grunenthal GmbH, Other Locations 59
Grunenthal GmbH, Subsidiaries 59
List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11